ArticleJournal of cancer research and clinical oncology2022

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.

Joseph Kauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.